In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

A recent study by the ICMR National Centre for Disease Informatics and Research warns of a 5.6% annual increase in Indian breast cancer cases, driven by various risk factors.

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

Angelina Jolie is reportedly preparing to leave Los Angeles behind as she plans a new life abroad focused on privacy, freedom ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Angelina Jolie's long-rumored relocation plans are very much alive and gaining momentum, according to close sources.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Angelina Jolie has shockingly faced a torrent of callous online abuse after boldly baring the scars from her double ...

Rare inherited genetic variants significantly increase familial lung cancer risk, offering new targets for early detection.

Hollywood star Angelina Jolie found herself at the center of an online firestorm after a new magazine photoshoot reignited ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...